Research progress on drug combination therapy against Candida albicans
10.12206/j.issn.2097-2024.202112019
- VernacularTitle:药物联用抑制白念珠菌生长的研究进展
- Author:
Zhongyu DENG
1
;
Shijin GUO
1
;
Yifan GUO
1
;
Juncheng FENG
1
;
Quanzhen LYU
2
;
Lijuan QIU
1
Author Information
1. School of Basic Medicine, Naval Medical University, Shanghai 200433, China.
2. School of Pharmacy, Naval Medical University, Shanghai 200433, China.
- Publication Type:Reviews
- Keywords:
Candida albicans;
combination therapy;
azole;
polyenes;
echinocandins;
photodynamic therapy;
ultrasonic therapy;
silver nanoparticles
- From:
Journal of Pharmaceutical Practice
2023;41(6):352-357
- CountryChina
- Language:Chinese
-
Abstract:
Candida albicans is one of the most common species of Candida, which is an important cause of invasive candidiasis in clinic. Due to the frequently use of classical antifungal agents, there are amounts of drug resistant C. albicans being isolated, causing the significantly decreasing of the efficacy of some antifungal agents in clinical treatment. Besides, the use of some compounds in clinic has been limited because of their toxicities. In such a context, drug combination therapy shows great potential on antifungal because of the synergy of different drugs or therapeutic methods that could bring, which could improve the weaknesses of single drug.
